Clinical and economic factors in the treatment of onychomycosis

PharmacoEconomics

Volumn 9, Issue 4, 1996, Pages 307-320

  Einarson, Thomas R ^a,b,c   Gupta, Aditya K ^b,d   Shear, Neil H ^b,d   Arikian, Steve ^a,e  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

^d SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^e Ctr for Health Outcomes Evaluation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOROLFINE; ANTIFUNGAL AGENT; CICLOPIRONE; GRISEOFULVIN; ITRACONAZOLE; TERBINAFINE; TIOCONAZOLE; UNCLASSIFIED DRUG;

CLINICAL TRIAL; HEALTH CARE COST; HUMAN; ONYCHOMYCOSIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; TOPICAL DRUG ADMINISTRATION;

EID: 0029928520     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199609040-00004     Document Type: Review

References (101)

1. Zaias N. Onychomycosis. Arch Dermatol 1972; 105: 263-74
2. Summerbell RC, Kane J, Krajden S. Onychomycosis, tinea pedis and tinea munuum caused by non-dermatophytic filamentous fungi. Mycoses 1989; 32: 609-19
3. Evans EGV. Nail dermatophytosis: the nature and scale of the problem. J Dermatol Treat 1990; 1: 47-8
4. Roberts DT. Prevalence of dermatophyte onychomycosis in the United Kingdom: results of an omnibus survey. Br J Dermatol 1992; 126: 23-7
5. Ramesh V, Reddy BSN, Singh R. Onychomycosis. Int J Dermatol 1983; 22: 148-52
6. Scher RK. Onychomycosis is more than a cosmetic problem. Br J Dermatol 1994; 130: 15
7. Dompmartin D, Dompmartin A, Deluol AM, et al. Onychomycosis and AIDS: treatment with topical ciclopirox olamine. Int J Dermatol 1990; 29: 233
8. Balfour JA, Faulds D. Terbinafine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses. Drugs 1492; 43: 254-84
9. Prevalence, morbidity, and cost of dermatological diseases. J Invest Dermatol 1979; 75: 395-401
10. Rosenthal SA, Wise RS. Studies concerning the development of resistance to griseofulvin by dermatophytes. Arch Dermatol 1960; 81: 684-8
11. Gupta AK, Sander DN, Shear NH. Antifungal agents: an overview. Part II. J Am Acad Dermatol 1994; 30: 911-33
12. André J. Achten G. Onychomycosis. Int J Dermatol 1987; 26: 481-90
13. Elewski BE. Clinical pearl: diagnosis of onychomycosis. J Am Acad Dermatol 1995; 32: 500-1
14. Stiller MJ, Sangueza OP, Slue W, et al. Dental curettes: useful tools for obtaining nail material for mycologic examination Cutis 1993; 52: 116
15. Daniel III CR. Nail micronizer. Cutis 1985; 36: 118
16. Taplin D. Zaias N. Isolation and recognition of dermatophytes on a new medium (DTM). Arch Dermatol 1969; 99: 203-9
17. Scher RK, Ackerman AB. Subtle clues to diagnosis from biopsies of nails. AmJ Dermatopathol 1980; 2: 55-6
18. Suarez SM, Silvers DN, Scher RK, et al. Histologic evaluation of nail clippings for diagnosing onychomycosis. Arch Dermatol 1991; 127: 1517-9
19. Daniel III CR. The diagnosis of nail fungal infection. Arch Dermatol 1991; 127: 1566-7
20. Goldfarb NJ, Sulzberger MB. Experiences in one hundred thirty-seven patients with oral griseofulvin. Arch Dermatol 1960; 81: 859-62
21. Pierard GE, Arrese-Estrada J, Pierard-Franchimont C. Treatment of onychomycosis: traditional approaches. J Am Acad Dermatol 1993; 29: S41-5
22. Hagermark O, Berlin A, Wallin I, et al. Plasma concentrations of griseofulvin in healthy volunteers and out-patients treated for onychomycosis. Acta Dermatol Venereol 1976; 56: 289-96
23. Hay RJ, Mackie RM, Clayton YM. Tioconazole nail solution - an open study of its efficacy in onychomycosis. Clin Exp Dermatol 1987; 10: 111-5
24. Hay RJ, Clayton YM, Moore MK. A comparison of tioconazole 28% nail solution versus base as an adjunct to oral griseofulvin in patients with onychomycosis. Clin Exp Dermatol 1987; 12: 175-7
25. Lauharanta J, Zaug M, Polak A, et al. Combination of amorolfine with griseofulvin: in vitro activity and clinical results in onychomycosis. JAMA Southeast Asia 1993; 9 Suppl. 4: 23-7
26. Hay RJ, Roberts DT, Doherty VR, et al. The topical treatment of onychomycosis using a new combined urea/imidazole preparation. Clin Exp Dermatol 1988; 13: 1647
27. Roberts DT, Hay RJ, Doherty VR. Topical treatment of onychomycosis using bifonazole 1% urea/40% paste. Ann N Y Acad Sci 1988; 544: 586-7
28. Torres-Rodriguez JM, Madrenys N, Nicolás MC. Non-traumatic topical treatment of onychomycosis with urea associated with bifonazole. Mycoses 1991; 34: 499-504
29. Hardjoko FS, Widyanto S, Singgih I, et al. Treatment of onychomycosis with a bitonazole-urea combination. Mycoses 1990; 33: 167-71
30. Nolting S. Non-traumatic removal of the nail and simultaneous treatment of onychomycosis. Dermatologica 1984; 169: 117-20
31. Ishii M, Hamada T, Asai Y. Treatment of onychomycosis by ODT therapy with 20% urea ointment and 2% tolnaftate ointment. Dermatologica 1983; 167: 273-9
32. Faergemann J, Swanbeck G. Treatment of onychomycosis with a propylene glycol-urea-lactic acid solution. Mycoses 1988; 32: 536-40
33. White MI, Clayton YM. The treatment of fungus and yeast infections of nails by the method of chemical removal. Clin Exp Dermatol 1982; 7: 273-6
34. South DA, Farber EM. Urea ointment in the nonsurgical avulsion of nail dystrophies - a reappraisal. Cutis 1980; 25: 609-12
35. Buselmeier TJ. Combination urea and salicylic acid ointment nail avulsion in nondystrophic nails: a follow-up observation. Cutis 1980; 25: 397,405
36. Dabrowa N, Landau JW, Newcomer VD. Antifungal activity of glutaraldehyde in vitro. Arch Dermatol 1972; 105: 555-7
37. Suringa DWR. Treatment of superficial onychomycosis with topically applied glutaraldehyde. Arch Dermatol 1970; 102: 163-7
38. Meyerson MS, Scher RK, Hochman LG, et al. Open-label study of the safety and efficacy of naftifine hydrochloride 1 percent gel in patients with distal subungual onychomycosis of the fingers. Cutis 1993; 51: 205-7
39. Klaschka F. Treatment of onychomycosis with naftifine gel. Mykosen 1987; 30 Suppl. 1: 119-23
40. Bentley-Phillips B. The treatment of onychomycosis with miconazole tincture. S Afr Med Tydskr Deel 1982; 62: 57-8
41. Wu YC, Chuan MT, Lu YC. Efficacy of ciclopirox olamine 1% cream in onychomycosis and tinea pedis. Mycoses 1991; 34: 93-5
42. Baden HP. Treatment of distal onychomycosis with avulsion and topical antifungal agents under occlusion. Arch Dermatol 1994; 130: 558-9
43. Zaug M, Bergstraesser M. Amorolfine in the treatment of onychomycoses and dermalomycoses (an overview). Clin Exp Dermatol 1992; 17: 61-70
44. Reinel D, Clarke C. Comparative efficacy and safety of amorolfine nail lacquer 5% in onychomycosis, once-weekly versus twice-weekly. Clin Exp Dermatol 1992; 17: 44-9
45. Geronemus RG. Laser surgery of the nail unit. J Dermatol Surg Oncol 1992; 18: 735-43
46. Rothermel E, Apfelberg DB. Carbon dioxide laser use for certain diseases of the toenails. Clin Podiatr Med Surg 1987; 4: 809-21
47. Apfelberg DB, Rothermel E, Widtfeldt A. Preliminary report on use of carbon dioxide laser in podiatry. J Am Podiatr Med Assoc 1984; 74: 509-13
48. Farber EM, South DA. Urea ointment in the nonsurgical avulsion of nail dystrophies. Cutis 1978; 22: 689-92
49. Baran R, Hay RJ. Partial surgical avulsion of the nail in onychomycosis. Clin Exp Dermatol 1985; 10: 413-8
50. Scher RK. Surgical avulsion of nail plates by a proximal to distal technique. J Dermatol Surg Oncol 1981; 7: 296-7
51. Rollman O. Treatment of onychomycosis by partial nail avulsion and topical miconazole. Dermatologica 1982; 165: 54-61
52. Hettinger D, Valinsky M. Treatment of onychomycosis with nail avulsion and topical ketoconazole. J Am Podiatr Med Assoc 1991; 81: 28-32
53. Brem J. Treating onychomycosis. Lancet 1977; 2: 937
54. Ontario Drug Benefit Formulary. Toronto: Ontario Ministry of Health, 1995
55. Epstein WL, Shah VP, Riegelman S. Griseofulvin levels in stratum corneum. Arch Dermatol 1972; 106: 344-8
56. Shah VP, Epslein WL, Riegelman S. Role of sweat in accumulation of orally administered griseofulvin in skin. J Clin Invest 1974; 53: 1673-8
57. Roth FJ, Blank H. The bioassay of griseofulvin in human stratum corneum. Arch Dermatol 1960; 81: 662-6
58. Meinhof W. Kinetics and spectrum of activity of oral antifungals: the therapeutic implications. J Am Acad Dermatol 1993; 29: S37-41
59. Alkiewicz J, Eckstein Z, Halweg H, et al. Fungistatic activity of some hydroxamic acids. Nature 1957; 180: 1204-5
60. Gentles JC. Experimental ringworm in guinea pigs: oral treatment with griseofulvin. Nature 1958; 182: 476-7
61. Lauder IM, O'Sullivan JG. Ringworm in cattle: prevention and treatment with griseofulvin. Vet Rec 1958; 70: 949-51
62. Williams DI, Marten RH, Sarkany I. Oral treatment of ringworm with griseofulvin. Lancet 1958; 2: 1212-3
63. Blank H, Smith JG, Roth FJ, et al. Griseofulvin for the systemic treatment of dermatomycoses. JAMA 1959; 171: 2168-74
64. Blank H, Roth FJ. The treatment of dermatomycoses with orally administered griseofulvin. Arch Dermatol 1959; 79: 259-6
65. Kruspel W. Zum gegenwärten stand der onychomykose-therapie mit griseofulvin. Wien Med Wochenschr 1964; 114: 576-82
66. Stevenson CJ, Djavahiszwili N. Chronic ringworm of the nails: long-term treatment with griseofulvin. Lancet 1961; 1: 373-4
67. Dillaha CJ, Jansen GT. Dosage requirements of griseofulvin in onychomycosis due to Trichophyton rubrum. Arch Dermatol 1960; 81: 192-8
68. Hargreaves GK. The treatment of onychomycosis with griseofulvin. Br J Dermatol 1960; 72: 359-64
69. Williams DI. Griseofulvin and Trichophyton rubrum infections. Arch Dermatol 1960; 81: 171-3
70. Davies RR, Everall JD, Hamilton E. Mycological and clinical evaluation of griseofulvin for chronic onychomycosis. BMJ 1967; 3: 464-8
71. Villars VV, Jones TC. Special features of the clinical use of oral terbinafine in the treatment of fungal diseases. Br J Dermatol 1992; 126: 61-9
72. Blank H. Commentary: treatment of dermatomycoses with griseofulvin. Arch Dermatol 1982; 118: 835-6
73. Hay RJ, Clay ton YM, Griffiths WAD, et al. A comparative double-blind study of ketoconazole and griseofulvin in dermatophytosis. Br J Dermatol 1985; 112: 691-6
74. Finlay AY. Pharmacokinetics of terbinafine in the nail. Br J Dermatol 1992; 126: 28-32
75. Faergemann J, Zehender H, Millerioux L. Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum corneum), sebum, hair and nails during and after 250 mg terbinafine orally once daily for 7 and 14 days. Clin Exp Dermatol 1994; 19: 121-6
76. Zaias N. Management of onychomycosis with oral terbinafine. J Am Acad Dermatol 1990; 23: 810-2
77. Goodfield MJD, Rowell NR, Forster RA, et al. Treatment of dermatophyte infection of the finger- and toe-nails with terbinafine (SF 86-327, Lamisil), an orally active fungicidal agent. Br J Dermatol 1989; 121: 753-7
78. Baudraz-Rosselet F, Rakosi T, Wili PB, et al. Treatment of onychomycosis with terbinafine. Br J Dermatol 1992; 126: 40-6
79. Van Der Schroeff JG, Cirkel PKS, Crijns MB, et al. A randomized treatment duration-finding study of terbinafine in onychomycosis. Br J Dermatol 1992; 126: 36-9
80. Goodfield MJD, Andrew L, Evans EGV. Short term treatment of dermatophyte onychomycosis with terbinafine. BMJ 1992; 304: 1151-4
81. Goodfield MJD. Clinicul results with terbinafine in onychomycosis. J Dermatol Treat 1990; 1: 55-7
82. Haneke E, Tausch I, Bräutigam M, et al. Short-duration treatment of fingernail dermatophytosis: a randomized, double-blind study with terbinafine and griseofulvin. J Am Acad Dermatol 1995; 32: 72-7
83. Faergemann J, Anderson C, Hersle K, et al. Double-blind, parallel-group comparison of terbinafine and griseofulvin in the treatment of toenail onychomycosis. J Am Acad Dermatol 1995; 32: 750-3
84. Matthieu L, De Doncker P, Cauwenbergh G, et al. Itraconazole penetrates the nail via the nail matrix and the nail bed - an investigation in onychomycosis. Clin Exp Dermatol 1991; 16: 374-6
85. Cauwenbergh G, Degreef H, Heykants J, et al. Pharmacokinetic profile of orally administered itraconazole in human skin. J Am Acad Dermatol 1988; 18: 263-8
86. Hay RJ, Clayton YM, Moore MK, et al. An evaluation of itraconuzole in the management of onychomycosis. Br J Dermatol 1988; 119: 359-66
87. Willemsen M, De Doncker P, Willems J, et al. Posttreatment itraconazole levels in the nail. J Am Acad Dermatol 1992; 26: 731-5
88. Roseeuw D, De Doncker P. New approaches to the treatment of onychomycosis. J Am Acad Dermatol 1993; 29: S45-50
89. De Doncker P, Decroix J, Piérard GE, et al. Antifungal pulse therapy in onychomycosis: a pharmacokinetic/pharmacodynamic investigation of monthly cycles of 1-week pulse with itraconazole. Arch Derm 1996; 132: 34-41
90. Faergemann J, Laufen H. Levels of fluconazole in serum, stratum corneum, epidermis-dermis (without stratum corneum) and eccrine sweat. Clin Exp Dermatol 1993; 18: 102-6
91. Wildfeuer A, Faergemann J, Laufen H, et al. Bioavailability of fluconazole in the skin after oral medication. Mycoses 1994; 37: 127-30
92. Coldiron B. Recalcitrant onychomycosis of the toenails successfully treated with fluconazole. Arch Dermatol 1992; 128: 909-10
93. Kuokkanen K, Alava S. Fluconazole in the treatment of onychomycosis caused by dermatophytes. J Dermatol Treat 1992; 3: 115-7
94. Goodfield MJD, Bosanquet N, Evans EGV. Cost effective clinical management of onychomycosis. Br J Med Econ 1994; 7: 15-23
95. Einarson TR, Arikian SR, Shear NH. Pharmacoeconomic analysis of oral treatments for onychomycosis: a Canadian study. J Res Pharm Econ 1995; 6 (1): 3-22
96. Lubeck DP, Patrick DL, McNulty P, et al. Quality of life of persons with onychomycosis. Qual Life Res 1993; 2: 341-8
97. Arikian SR, Einarson TR, Kobelt-Nguyen G, et al. A multinational pharmacoeconomic analysis of oral therapies for onychomycosis. Br J Dermatol 1994; 130: 35-44
98. Einarson T, Shear NH, Oh P. Models for pharmacoeconomic analysis. Can J Clin Pharmacol. In press
99. Kobelt-Nguyen G, van Assche D. Mycosis of finger and toe nails: pharmacoeconomic analysis of oral treatments in Germany [in German]. Z Allgemeinmed 1994; 70: 683-5
100. Bergman W, Rutten FF. Oral treatment of onychomycosis of the toenails: comparison of cost-effectiveness of griseofulvin, itraconazole, ketoconazole, and lerbinafine [in Dutch]. Ned Tijdschr Geneeskd 1994; 138 (47): 2346-50
101. Meinhof W, Girardi RM, Stracke A. Patient noncompliance in dermatomycosis. Dermatologica 1984; 169 Suppl. 1: 57-66